The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Apart from the pretty green boxes on my screen, I'm going to assume everyone is in agrmt that an NHS contract is on its way.
The question is how big? I don't think it will be as straightforward as the Gov saying here's a £1bn, do your best. All the sales / NHS manager roles talking about growing market share / increasing sales to NHS so I think we will get a chunky order up front but with scope to increase sales over a minimum 2 year period.
I've seen him like previous posts. Unfortunately I do not think it is the Roche Group. Anyone familiar with Youseq? Their CEO has liked it. They are next gen sequencing experts - I can't work out whether they would add anything to our arsenal?
The similarities between late last Summer and now are uncanny:
40%+ drop in sp
Massive recruitment drive
Public thinking covid will soon be over
Amazing product related RNS's that do little to the sp
Shorts
Anticipated gov contracts
Talk of T/O's, MM manipulation, GM being incompetent
Please remember that past performance may not be indicative of future results (but it is sure looking good to me).
Also another 26 cases of the variant first detected in South Africa https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data
https://www.jpost.com/health-science/coronavirus-has-israel-reached-herd-immunity-662075
Yamin said that in the near future, the coronavirus should enter a state of “silent epidemic” meaning that there would not be massive infection and certainly less strain on the health system. This is especially so because the majority of children do not develop serious cases of COVID-19.
But he said that while the disease is still spreading, Israel should proactively test the population to catch asymptomatic cases before they spread, especially in areas where people could be at the highest risk, such as in senior living facilities.
Interesting thoughts as to which way the PCR market may go.
https://www.technologynetworks.com/diagnostics/articles/rt-qpcrfacts-and-fallacies-an-interview-with-professor-stephen-bustin-346520
Studies in India back up the findings cited in the Welsh policy document.
PCR pre surgery could become the norm in all developed countries...
https://www.google.com/amp/s/www.hindustantimes.com/india-news/covid-high-death-risk-after-surgery-within-6-weeks-of-testing-ve-saysstudy-101615433312660-amp.html
Our Guillermo is a heavyweight.
Executive Vice President Global Marketing, Sales & Communications Siemens Healthineers Diagnostics
Dates Employed2018 – 2020
Employment Duration2 yrs
LocationTarrytown, New York
Member of the Diagnostics Global Executive Team. Developed and executed global In-Vitro commercial strategies and roadmaps including market and customer segmentation, portfolio positioning and placement, branding and media strategies as well as channel and sales strategies focused on improving market position and business volume for the diagnostics business. Managed more than 4B USD in sales volume. Led 8 vice presidents managing more than 350 overall staff.
see less
TitlePresident Latin America
Dates Employed2015 – 2018
Employment Duration3 yrs
LocationSantiago, Chile
Part of global executive team as one of six regional presidents responsible for the Healthcare Latin American business. Defined comprehensive regional business strategy (go to market, structure, portfolio, processes and shared services). Supervised team of 1,600+ personnel including zones/country managing directors, regional business area leaders and support function managers. Managed USD $850M+ in business volume.
https://www.linkedin.com/in/guillermo-raimondo/?originalSubdomain=cl
https://coronavirus.data.gov.uk/details/vaccinations
The numbers of those receiving the first dose seem to be going down, from about 400k a day to 160k. This doesn't tell the whole picture because those daily second doses have gone up by about 50k a day.
Possibly shows that they can't keep up the relentless early pace that was set.
On the BBC news live stream it says this at about ten last 5:
A quarter of all Covid cases are being checked for variants and all the indications are that they are not spreading.
The new P.1 cases mean the total is now 10, while there have been just over 300 cases of the South Africa variant and another 113 cases where the UK virus has acquired the E484 mutation which allows it to escape some of the immune response.
Question: if they are only checking 1/4 of cases does this mean that the number of variant cases could be 4 times higher?
The job vacancy summary for the above role certainly suggests that all is good with the NHS:
Reporting to the Regional Sales Manager for South UK, you will be responsible for direct sales and driving adoption of
Novacyt’s products into NHS accounts within your territory.
This role will be pivotal to build a platform for future business with the NHS. The candidate will display a clear drive to win
new business and develop new relationships from the ground up. Previous experience of the NHS sales process is critical,
with contacts within key Pathology departments.
Activity will focus on Novacyt’s COVID-19 clinical diagnostic portfolio and related products within Novacyt Group. You will
be expected to quickly identify, develop, maintain and strengthen relationships to ensure that you are gaining the highest
amount of revenue for the business and adoption of our products in the NHS. A sense of urgency will be key as the role will
involve working in a fast-paced environment where actions need to be taken quickly and executed efficiently.
By my calculations, Phase 1 comes to an end on March 28th so we ought to hear something in and around then. Hopefully when we do, illogical drops such as today will be a thing of the past.
I have done my bit by buying as many shares as possible and leaving GM to crack on with it. If it wasn't for the radio silence we would not have had this amazing opportunity to buy at these prices.
One of the other companies I had invested in RNS'd the fact they were attending a conference - if we ever get to that stage, I am out.
No new info here but for anyone else just catching up we've had some fantastic news since cob Friday:
1) LFT tender, lots of discussion about this may negatively impact sp (and I guess it could short term) but confirms UK gov still throwing billions at testing
2) GGGG's finding out Wales policy to PCR test pre- elective surgery and periodically thereafter whilst in hospital. Ordinarily there are c 8 mil elective operations in UK so that's lots of PCR tests (I tried to find it the average time someone spends in hospital to estimate how many but I couldn't find out).
3) relief package in US almost good to go. Huge testing spending.
4) Routys amazing manc airport, q machines find
5) PCR for Eurotunnel travel.
6) Han**** reiterating importance of gernomic surveillance in his briefing on Friday.
7) talk of next winter already hitting the news...winterplex.